Vgt Engineers Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-07-2024
- Paid Up Capital ₹ 0.10 M
as on 09-07-2024
- Company Age 26 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 40.00 M
as on 09-07-2024
- Revenue 4.20%
(FY 2020)
- Profit 67.72%
(FY 2020)
- Ebitda 31.01%
(FY 2020)
- Net Worth -0.24%
(FY 2020)
- Total Assets -0.16%
(FY 2020)
About Vgt Engineers Pharma
The Company is engaged in the Engineering Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹4.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Daksha Thanawala and Varun Thanawala serve as directors at the Company.
- CIN/LLPIN
U29297MH1998PTC116309
- Company No.
116309
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vgt Engineers Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Daksha Thanawala  | Director | 21-Aug-1998 | Current |
| Varun Thanawala | Director | Current |
Financial Performance and Corporate Structure Insights of Vgt Engineers Pharma.
Vgt Engineers Pharma Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.2% increase. The company also saw a substantial improvement in profitability, with a 67.72% increase in profit. The company's net worth dipped by a decrease of 0.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vgt Engineers Pharma?
In 2020, Vgt Engineers Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Oros Labs Private Limited
Active 38 years 7 monthsDaksha Thanawala and Varun Thanawala are mutual person
Thanawala Motor Agency Private Limited
Active 28 years 7 monthsDaksha Thanawala and Varun Thanawala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Thane Bharat Sahakari Bank Limited Creation Date: 11 Jul 2014 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Vgt Engineers Pharma?
Unlock and access historical data on people associated with Vgt Engineers Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vgt Engineers Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vgt Engineers Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
